NVO's key patent for semaglutide has expired in India, with $14 generics hitting the market, and China's patent is expiring soon. The introduction of ultra-cheap generics in the world's two most populous countries will severely undercut NVO's pricing power and capture international market share. The international patent cliff for NVO's blockbuster drugs creates a bearish headwind for the stock's global growth narrative. NVO's primary revenue and profit centers are the US and Europe, where patents remain intact and demand still vastly outstrips supply.
NVO
HIGH
Mar 23, 00:55
Key Points
['Semaglutide patent expired in India.', '$14 generics already in market.', 'China patent expiration is imminent.', 'Threatens international growth/margins.']
March 23, 2026 at 00:55